{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T06:10:25Z","timestamp":1698214225076},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T00:00:00Z","timestamp":1205712000000},"content-version":"vor","delay-in-days":5158,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1994,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>OBJECTIVE <\/jats:bold> Several studies indicate an inverse relationship between the sympathetic nervous system activity and thyroid function. Altered adrenoceptor sensitivity, particularly \u03b1 and \u03b2, have been described in hypothyroid and hyperthyroid patients. No information in patients with thyroid disease is available on the main mechanism regulating sympathetic nervous system outflow, i.e. the \u03b1<jats:sup>2<\/jats:sup>\u2010adrenoceptor pathway. In our study we evaluated \u03b1<jats:sup>2<\/jats:sup>\u2010adrenergic activity in patients with thyroid disease by the assessment of cardiovascular and catecholamine response to clonidine, a central a<jats:sub>2<\/jats:sub> adrenergic agonist.<\/jats:p><jats:p><jats:bold>PATIENTS <\/jats:bold> Ten patients with hypothyroidism, six patients with hyperthyroidism before and during adequate therapy, and ten healthy subjects.<\/jats:p><jats:p><jats:bold>MEASUREMENTS <\/jats:bold> After three blood samples for the basal determination of noradrenaline and adrenaline, the subjects swallowed 4 \u03bcg\/kg body weight of clonidine. Blood pressure and pulse rate were measured 30,60,90,120,130 and 140 minutes after clonidine administration; blood samples for determination of catecholamines were drawn at 120,130 and 140 minutes.<\/jats:p><jats:p><jats:bold>RESULTS <\/jats:bold> At presentation the decrease in plasma noradrenaline after clonidine in the patients was similar to that of the control group (hypothyroids: 1.07 \u00b1 0.23 nmol\/l mean\u00b1SEM; hyperthyroids: 0.54 \u00b1 0 06 nmol\/l; controls: 0.36\u00b10.10 nmol\/l; <jats:italic>F<\/jats:italic>=1.2, <jats:italic>P<\/jats:italic>=NS). No differences were detected in the fall in adrenaline and mean arterial pressure (MAP) after clonidine. The adequate therapy induced in hypothyroid patients a decrease in the basal levels of noradrenaline (1.88\u00b10.28 <jats:italic>vs<\/jats:italic> 0.67\u00b10.10 nmol\/l; <jats:italic>P<\/jats:italic> &lt;0.05) and a lesser fall in mean arterial pressure after clonidine (AMAP 20 4 \u00b1 2 0 <jats:italic>vs<\/jats:italic> 9.7 \u00b12.8 mmHg; <jats:italic>P<\/jats:italic> &lt; 0.05). No variations were detected in hyperthyroid patients after therapy either in basal hormones levels or in the magnitude of decrement in MAP and noradrenaline induced by clonidine.<\/jats:p><jats:p><jats:bold>CONCLUSIONS <\/jats:bold> We conclude that in spite of the previously reported abnormalities in \u03b1<jats:sub>1<\/jats:sub> and \u03b2\u2010adrenergic receptor activity, the inhibitory \u03b1<jats:sub>2<\/jats:sub>\u2010receptor pathway is normal in patients with altered thyroid function.<\/jats:p>","DOI":"10.1111\/j.1365-2265.1994.tb02474.x","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T10:59:47Z","timestamp":1205751587000},"page":"235-239","source":"Crossref","is-referenced-by-count":3,"title":["\u03b12\u2010Adrenergic activity is normal in patients with thyroid disease"],"prefix":"10.1111","volume":"40","author":[{"given":"Graziano","family":"Del Rio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Zizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Marrama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Venneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano Delia","family":"Casa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Velardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,17]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00613922"},{"key":"e_1_2_1_3_1","first-page":"1067","article-title":"Urinary excretion of free catecholamines in Graves' disease","volume":"49","author":"Bayliss R.I.S.","year":"1971","journal-title":"Endocrinology"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-4-4-378"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1989.tb00268.x"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-35-3-359"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-44-6-1185"},{"key":"e_1_2_1_8_1","first-page":"465","article-title":"Sex differences in the catecholamine response to clonidine","volume":"17","author":"Del Rio G.","year":"1993","journal-title":"International Journal of Obesity"},{"key":"e_1_2_1_9_1","unstructured":"Dimsdale J.E.&Ziegler M.J.(1991)What do plasma and urinary measures of catecholamines tell us about human response to stressorsCirculation (Suppl. 2) 36\u201342."},{"key":"e_1_2_1_10_1","first-page":"363","volume-title":"Statistics for Research","author":"Dowdy S.","year":"1983"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.68.3.827"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1042\/cs0620247"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1990.70.4.963"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1990.tb00481.x"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/geronj\/42.3.271"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(79)90384-9"},{"key":"e_1_2_1_17_1","first-page":"61","volume-title":"Endocrine Mechanisms in Hypertension","author":"Klein I.","year":"1989"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.9"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.22.5.559"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90533-J"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113961"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1984.tb00120.x"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(90)90182-O"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-1-277"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-6-1761"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-66-2-438"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/10641968509073606"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(87)90022-9"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112611"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.5.1.112"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-113-1-354"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-59-1-151"},{"key":"e_1_2_1_33_1","first-page":"433","article-title":"Lack of desensitization of alpha\u20102\u2010mediated inhibition of lipolysis in fat cells after acute and chronic treatment with clonidine","volume":"233","author":"Villeneuve A.","year":"1985","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.3.3.340"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00561067"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.1994.tb02474.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.1994.tb02474.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T02:37:56Z","timestamp":1698115076000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.1994.tb02474.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1994,2]]}},"alternative-id":["10.1111\/j.1365-2265.1994.tb02474.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.1994.tb02474.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,2]]}}}